An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.
Key facts
- Where
- Guangzhou, KínaSee the site
- Phase
- 2. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Forrás: NCT07863167: ki vehet részt
Where in Kína
- Guangdong Provincial People's HospitalGuangzhou, KínaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Trial code
- NCT07863167
- Record updated
- 2026. november 9.
- Original description
The study is being conducted to evaluate the efficacy, and safety of SHR-A2009 combined with other anti-tumor therapies for perioperative treatment of resectable non-small cell lung cancer in adults.Read full original descriptionShow less
The study is being conducted to evaluate the efficacy, and safety of SHR-A2009 combined with other anti-tumor therapies for perioperative treatment of resectable non-small cell lung cancer in adults.
Inclusion: voluntarily participate in this clinical study, understand the research procedure and be able to sign the informed consent in writing ; At the time of signing the informed consent form, the age is 18-70 years old ( including both ends ), both men and women can; The ECOG score was 0 or 1; Pathologically confirmed NSCLC, assessed as resectable or previously resected (R0); Adequate bone marrow and organ function.
Exclusion: Participants who received systemic immunostimulatory therapy within 4 weeks prior to the first dose; Participants who received systemic immunosuppressive therapy within 2 weeks before the first dose; Participants with a history of interstitial pneumonia or cannot exclude interstitial pneumonia; or there are other moderate to severe lung diseases that may affect respiratory function. Or received previous pneumonectomy surgery; There were clinically significant bleeding symptoms or obvious bleeding tendency within 1 month before the first administration; Arterial and venous thrombosis events occurred within 3 months before the first administration; Participants with active hepatitis B or C; 1.Evidence of active tuberculosis infection within 1 year before the first administration; 12.Severe infection occurred within 4 weeks before the first administration. 13.History of severe allergic reactions to other monoclonal antibody / fusion protein drugs; Participants with active, known or suspected autoimmune diseases; Other malignant tumors within 5 years before screening; Participants with severe cardiovascular and cerebrovascular diseases; HIV test positive; Allergy to any component of the treatment regimen. 15.Participants were known to have a history of psychotropic drug abuse, alcohol abuse or drug abuse.